CytomX highlights Varseta-M EpCAM Topo-1 ADC data in late-line metastatic colorectal cancer presentation
CTMX•Safety update and balance sheet
Safety update cited manageable adverse events; diarrhea was the most common Grade 3 TRAE at 24%, falling to 10% in dose-optimization with prophylaxis.
Cash totaled $330 million as of Q2 2026; runway projected into the second half of 2028; additional $37 million received from Regeneron.
Conference presentation highlights Varseta-M data
CytomX presented at the Wells Fargo 21st Annual Healthcare Conference, highlighting its Probody masked-therapeutics platform and oncology pipeline.
Varsetatug masetecan (Varseta-M), an EpCAM-directed Topo-1 ADC, showed confirmed ORR of 20% at 8.6 mg/kg, 32% at 10 mg/kg in late-line CRC.
Preliminary PFS measured 6.8 months at 8.6 mg/kg, 7.1 months at 10 mg/kg; FDA Fast Track granted for relapsed/refractory mCRC.
